RANK Ligand, FREE Soluble, Human, ELISA Kit, High Sensitivity (12x8tests)

データシート

• 商品コード：BI-20462
• メーカー：BMC
• 包装：1kit
• 価格： ¥184,000
• 在庫：無(未発注)

マイリストに追加 マイリストに追加済

• No.： 1
• 文献情報：
  Kulcsar-Jakab E et al. Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a cross-sectional, observational study. BMC Musculoskelet Disord 2015 Aug;16:227
  Kulcsar-Jakab E et al
  2015/01/01
  
• 備考：
  
• 参照：
  

• No.： 2
• 文献情報：
  Melchiorre D et al. RANK-RANKL-OPG in hemophilic arthropathy: from clinical and imaging diagnosis to histopathology. J. Rheumatol. 2012 Aug;39(8):1678-86
  Melchiorre D et al
  2012/01/01
  
• 備考：
  
• 参照：
  

• No.： 3
• 文献情報：
  Spatz JM et al. Serum sclerostin increases in healthy adult men during bed rest. J. Clin. Endocrinol. Metab. 2012 Sep;97(9):E1736-40
  Spatz JM et al
  2012/01/01
  
• 備考：
  
• 参照：
  

• No.： 4
• 文献情報：
  Jansen RB et al. Bone mineral density and markers of bone turnover and inflammation in diabetes patients with or without a Charcot foot: An 8.5-year prospective case-control study. J. Diabetes Complicat. 2018 02;32(2):164-170
  Jansen RB et al
  2018/01/01
  
• 備考：
  
• 参照：
  

• No.： 5
• 文献情報：
  Telejko B et al. The association of bone turnover markers with pro- and anti-inflammatory adipokines in patients with gestational diabetes. Ann Agric Environ Med 2015;22(2):307-12
  Telejko B et al
  2015/01/01
  
• 備考：
  
• 参照：
  

• No.： 6
• 文献情報：
  Jasiewicz M et al. Enhanced IL-6 trans-signaling in pulmonary arterial hypertension and its potential role in disease-related systemic damage. Cytokine 2015 Dec;76(2):187-192
  Jasiewicz M et al
  2015/01/01
  
• 備考：
  
• 参照：
  

• No.： 7
• 文献情報：
  Faienza MF et al. Mechanisms of enhanced osteoclastogenesis in girls and young women with Turner"s Syndrome. Bone 2015 Dec;81:228-236
  Faienza MF et al
  2015/01/01
  
• 備考：
  
• 参照：
  

• No.： 8
• 文献情報：
  Rakic M et al. CD14 and TNFα single nucleotide polymorphisms are candidates for genetic biomarkers of peri-implantitis. Clin Oral Investig 2015 May;19(4):791-801
  Rakic M et al
  2015/01/01
  
• 備考：
  
• 参照：
  

• No.： 9
• 文献情報：
  Ostrowska Z et al. Selected pro-inflammatory cytokines, bone metabolism, osteoprotegerin, and receptor activator of nuclear factor-kB ligand in girls with anorexia nervosa. Endokrynol Pol 2015;66(4):313-21
  Ostrowska Z et al
  2015/01/01
  
• 備考：
  
• 参照：
  

• No.： 10
• 文献情報：
  Gaudio A et al. Decreased bone cortical density at the forearm in subjects with subclinical peripheral arterial disease. Osteoporos Int 2015 Jun;26(6):1747-53
  Gaudio A et al
  2015/01/01
  
• 備考：
  
• 参照：
  

• No.： 11
• 文献情報：
  Tohidi M et al. Omentin-1, visfatin and adiponectin levels in relation to bone mineral density in Iranian postmenopausal women. Bone 2012 Nov;51(5):876-81
  Tohidi M et al
  2012/01/01
  
• 備考：
  
• 参照：
  

• No.： 12
• 文献情報：
  Onuma T et al. Levels of osteoclastogenesis-related factors in the peri-implant crevicular fluid and clinical parameters of immediately loaded implants in patients with osteopenia: a short-term report. Int J Oral Maxillofac Implants ;30(6):1431-6
  Onuma T et al
  
• 備考：
  
• 参照：
  

• No.： 13
• 文献情報：
  Chun EH et al. Polymorphisms in neuropeptide genes and bone mineral density in Korean postmenopausal women. Menopause 2015 Nov;22(11):1256-63
  Chun EH et al
  2015/01/01
  
• 備考：
  
• 参照：
  

• No.： 14
• 文献情報：
  Woo JH et al. Cannabinoid receptor gene polymorphisms and bone mineral density in Korean postmenopausal women. Menopause 2015 May;22(5):512-9
  Woo JH et al
  2015/01/01
  
• 備考：
  
• 参照：
  

• No.： 15
• 文献情報：
  Anastasilakis AD et al. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers. Metab. Clin. Exp. 2015 Oct;64(10):1291-7
  Anastasilakis AD et al
  2015/01/01
  
• 備考：
  
• 参照：
  

• No.： 16
• 文献情報：
  Bonf叩 AC et al. RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus. Osteoporos Int 2015 May;26(5):1563-71
  Bonf叩 AC et al
  2015/01/01
  
• 備考：
  
• 参照：
  

• No.： 17
• 文献情報：
  Grasemann C et al. Loss of Functional Osteoprotegerin: More Than a Skeletal Problem. J. Clin. Endocrinol. Metab. 2017 01;102(1):210-219
  Grasemann C et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 18
• 文献情報：
  Pereira RMR et al. Associations between OPG and RANKL polymorphisms, vertebral fractures, and abdominal aortic calcification in community-dwelling older subjects: the Sao Paulo Ageing & Health Study (SPAH). Osteoporos Int 2016 11;27(11):3319-3329
  Pereira RMR et al
  2016/01/01
  
• 備考：
  
• 参照：
  

• No.： 19
• 文献情報：
  Stuss M et al. Assessment of OPG, RANKL, bone turnover markers serum levels and BMD after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis. Endokrynol Pol 2016;67(2):174-84
  Stuss M et al
  2016/01/01
  
• 備考：
  
• 参照：
  

• No.： 20
• 文献情報：
  Caparbo VF et al. Monocytes from male patients with ankylosing spondylitis display decreased osteoclastogenesis and decreased RANKL/OPG ratio. Osteoporos Int 2018 Nov;29(11):2565-2573
  Caparbo VF et al
  2018/01/01
  
• 備考：
  
• 参照：
  

• No.： 21
• 文献情報：
  Lieb W et al. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler. Thromb. Vasc. Biol. 2010 Sep;30(9):1849-54
  Lieb W et al
  2010/01/01
  
• 備考：
  
• 参照：
  

• No.： 22
• 文献情報：
  Stern A et al. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur. J. Endocrinol. 2007 May;156(5):555-62
  Stern A et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 23
• 文献情報：
  Angelopoulos NG et al. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with beta-thalassemia major. J. Bone Miner. Metab. 2007;25(1):60-7
  Angelopoulos NG et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 24
• 文献情報：
  Ueland T et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005 May;111(19):2461-8
  Ueland T et al
  2005/01/01
  
• 備考：
  
• 参照：
  

• No.： 25
• 文献情報：
  Franchimont N et al. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohns disease patients. Clin. Exp. Immunol. 2004 Dec;138(3):491-8
  Franchimont N et al
  2004/01/01
  
• 備考：
  
• 参照：
  

• No.： 26
• 文献情報：
  Uluçkan Ö et al. Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts. Sci Transl Med 2016 Mar;8(330):330ra37
  Uluçkan Ö et al
  2016/01/01
  
• 備考：
  
• 参照：
  

• No.： 27
• 文献情報：
  Kushlinskii NE et al. Receptor Activator of Nuclear Transcription Factor NF-κB (RANK), Its Ligand RANKL, and Natural Inhibitor of RANKL Osteoprotegerin (OPG) in the Blood Serum of Patients with Primary Bone Tumors. Bull. Exp. Biol. Med. 2017 Aug;163
  Kushlinskii NE et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 28
• 文献情報：
  Tohyama R et al. Establishment of a xenograft model to explore the mechanism of bone destruction by human oral cancers and its application to analysis of role of RANKL. J. Oral Pathol. Med. 2016 May;45(5):356-64
  Tohyama R et al
  2016/01/01
  
• 備考：
  
• 参照：
  

• No.： 29
• 文献情報：
  Starup-Linde J et al. Differences in biochemical bone markers by diabetes type and the impact of glucose. Bone 2016 Feb;83:149-155
  Starup-Linde J et al
  2016/01/01
  
• 備考：
  
• 参照：
  

• No.： 30
• 文献情報：
  Nakahara T et al. Fibroblast growth factor 23 inhibits osteoblastic gene expression and induces osteoprotegerin in vascular smooth muscle cells. Atherosclerosis 2016 10;253:102-110
  Nakahara T et al
  2016/01/01
  
• 備考：
  
• 参照：
  

• No.： 31
• 文献情報：
  Fonolla-Joya J et al. Daily Intake of Milk Enriched with n-3 Fatty Acids, Oleic Acid, and Calcium Improves Metabolic and Bone Biomarkers in Postmenopausal Women. J Am Coll Nutr 2016 08;35(6):529-536
  Fonolla-Joya J et al
  2016/01/01
  
• 備考：
  
• 参照：
  

• No.： 32
• 文献情報：
  Giuliani N et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 2002 Dec;100(13):4615-21
  Giuliani N et al
  2002/01/01
  
• 備考：
  
• 参照：
  

• No.： 33
• 文献情報：
  Chan BY et al. Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. Clin. Chem. 2003 Dec;49(12):2083-5
  Chan BY et al
  2003/01/01
  
• 備考：
  
• 参照：
  

• No.： 34
• 文献情報：
  Terpos E et al. Unusual association between increased bone resorption and presence of paroxysmal nocturnal hemoglobinuria phenotype in multiple myeloma. Int. J. Hematol. 2003 Nov;78(4):344-8
  Terpos E et al
  2003/01/01
  
• 備考：
  
• 参照：
  

• No.： 35
• 文献情報：
  Hawa G et al. Immunoassay for soluble RANKL (receptor activator of NF-kappaB ligand) in serum. Clin. Lab. 2003;49(9-10):461-3
  Hawa G et al
  2003/01/01
  
• 備考：
  
• 参照：
  

• No.： 36
• 文献情報：
  Feuerherm AJ et al. Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scand. J. Rheumatol. 2001;30(4):229-34
  Feuerherm AJ et al
  2001/01/01
  
• 備考：
  
• 参照：
  

• No.： 37
• 文献情報：
  Colucci S et al. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 2004 Dec;104(12):3722-30
  Colucci S et al
  2004/01/01
  
• 備考：
  
• 参照：
  

• No.： 38
• 文献情報：
  Hofbauer LC et al. Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. Clin. Endocrinol. (Oxf) 2004 Feb;60(2):214-9
  Hofbauer LC et al
  2004/01/01
  
• 備考：
  
• 参照：
  

• No.： 39
• 文献情報：
  Pennisi P et al. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos Int 2004 May;15(5):389-95
  Pennisi P et al
  2004/01/01
  
• 備考：
  
• 参照：
  

• No.： 40
• 文献情報：
  Dai SM et al. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. Ann. Rheum. Dis. 2004 Nov;63(11):1379-86
  Dai SM et al
  2004/01/01
  
• 備考：
  
• 参照：
  

• No.： 41
• 文献情報：
  Skoumal M et al. Serum osteoprotegerin but not receptor activator of NF-kappaB ligand correlates with Larsen score in rheumatoid arthritis. Ann. Rheum. Dis. 2004 Feb;63(2):216-7
  Skoumal M et al
  2004/01/01
  
• 備考：
  
• 参照：
  

• No.： 42
• 文献情報：
  Schett G et al. Soluble RANKL and risk of nontraumatic fracture. JAMA 2004 Mar;291(9):1108-13
  Schett G et al
  2004/01/01
  
• 備考：
  
• 参照：
  

• No.： 43
• 文献情報：
  Buzi F et al. Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turners syndrome and rheumatoid arthritis. Clin. Endocrinol. (Oxf) 2004 Jan;60(1):87-91
  Buzi F et al
  2004/01/01
  
• 備考：
  
• 参照：
  

• No.： 44
• 文献情報：
  F叩brega E et al. Osteoprotegerin and RANKL in alcoholic liver cirrhosis. Liver Int. 2005 Apr;25(2):305-10
  F叩brega E et al
  2005/01/01
  
• 備考：
  
• 参照：
  

• No.： 45
• 文献情報：
  Ma誰moun L et al. Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury. Calcif. Tissue Int. 2005 Jun;76(6):404-11
  Ma誰moun L et al
  2005/01/01
  
• 備考：
  
• 参照：
  

• No.： 46
• 文献情報：
  Liu JM et al. Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75. Calcif. Tissue Int. 2005 Jan;76(1):1-6
  Liu JM et al
  2005/01/01
  
• 備考：
  
• 参照：
  

• No.： 47
• 文献情報：
  Schoppet M et al. Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. Circulation 2003 Mar;107(11):e76; author reply e76
  Schoppet M et al
  2003/01/01
  
• 備考：
  
• 参照：
  

• No.： 48
• 文献情報：
  Terpos E et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003 Aug;102(3):1064-9
  Terpos E et al
  2003/01/01
  
• 備考：
  
• 参照：
  

• No.： 49
• 文献情報：
  Szalay F et al. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J. Hepatol. 2003 Apr;38(4):395-400
  Szalay F et al
  2003/01/01
  
• 備考：
  
• 参照：
  

• No.： 50
• 文献情報：
  Hegedus D et al. Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease. J. Bone Miner. Res. 2002 Nov;17(11):1961-7
  Hegedus D et al
  2002/01/01
  
• 備考：
  
• 参照：
  

• No.： 51
• 文献情報：
  Whyte MP et al. Osteoprotegerin deficiency and juvenile Pagets disease. N. Engl. J. Med. 2002 Jul;347(3):175-84
  Whyte MP et al
  2002/01/01
  
• 備考：
  
• 参照：
  

• No.： 52
• 文献情報：
  Salda単a L et al. Osteoblast response to thermally oxidized Ti6Al4V alloy. J Biomed Mater Res A 2005 Apr;73(1):97-107
  Salda単a L et al
  2005/01/01
  
• 備考：
  
• 参照：
  

• No.： 53
• 文献情報：
  Terpos E et al. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. Leukemia 2004 Aug;18(8):1420-6
  Terpos E et al
  2004/01/01
  
• 備考：
  
• 参照：
  

• No.： 54
• 文献情報：
  Voskaridou E et al. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br. J. Haematol. 2003 Nov;123(4):730-7
  Voskaridou E et al
  2003/01/01
  
• 備考：
  
• 参照：
  

• No.： 55
• 文献情報：
  Seminari E et al. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Med. 2005 May;6(3):145-50
  Seminari E et al
  2005/01/01
  
• 備考：
  
• 参照：
  

• No.： 56
• 文献情報：
  von Tirpitz C et al. Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohns disease. Eur J Gastroenterol Hepatol 2003 Nov;15(11):1165-70
  von Tirpitz C et al
  2003/01/01
  
• 備考：
  
• 参照：
  

• No.： 57
• 文献情報：
  Avbersek-Luznik I et al. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? Nephrol. Dial. Transplant. 2005 Mar;20(3):566-70
  Avbersek-Luznik I et al
  2005/01/01
  
• 備考：
  
• 参照：
  

• No.： 58
• 文献情報：
  Alvarez L et al. Serum osteoprotegerin and its ligand in Pagets disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Arthritis Rheum. 2003 Mar;48(3):824-8
  Alvarez L et al
  2003/01/01
  
• 備考：
  
• 参照：
  

• No.： 59
• 文献情報：
  Elhasid R et al. Familial severe congenital neutropenia associated with infantile osteoporosis: a new entity. Am. J. Hematol. 2003 Jan;72(1):34-7
  Elhasid R et al
  2003/01/01
  
• 備考：
  
• 参照：
  

• No.： 60
• 文献情報：
  Zhao HY et al. The influence of Lys3Asn polymorphism in the osteoprotegerin gene on bone mineral density in Chinese postmenopausal women. Osteoporos Int 2005 Dec;16(12):1519-24
  Zhao HY et al
  2005/01/01
  
• 備考：
  
• 参照：
  

• No.： 61
• 文献情報：
  Helske S et al. Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload. Eur. J. Heart Fail. 2007 Apr;9(4):357-63
  Helske S et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 62
• 文献情報：
  Lu Y et al. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Res. 2007 Apr;67(8):3646-53
  Lu Y et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 63
• 文献情報：
  Shroff RC et al. The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol. Dial. Transplant. 2008 Oct;23(10):3263-71
  Shroff RC et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 64
• 文献情報：
  Syversen SW et al. Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression. J. Rheumatol. 2009 Feb;36(2):266-72
  Syversen SW et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 65
• 文献情報：
  Mencej-Bedrac S et al. The combinations of polymorphisms in vitamin D receptor, osteoprotegerin and tumour necrosis factor superfamily member 11 genes are associated with bone mineral density. J. Mol. Endocrinol. 2009 Mar;42(3):239-47
  Mencej-Bedrac S et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 66
• 文献情報：
  Ndip A et al. The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy. Diabetes 2011 Aug;60(8):2187-96
  Ndip A et al
  2011/01/01
  
• 備考：
  
• 参照：
  

• No.： 67
• 文献情報：
  Assadi M et al. Correlation of circulating omentin-1 with bone mineral density in multiple sclerosis: the crosstalk between bone and adipose tissue. PLoS ONE 2011;6(9):e24240
  Assadi M et al
  2011/01/01
  
• 備考：
  
• 参照：
  

• No.： 68
• 文献情報：
  Yuan LQ et al. RANKL is a downstream mediator for insulin-induced osteoblastic differentiation of vascular smooth muscle cells. PLoS ONE 2011;6(12):e29037
  Yuan LQ et al
  2011/01/01
  
• 備考：
  
• 参照：
  

• No.： 69
• 文献情報：
  Stavroulopoulos A et al. Evolution of coronary artery calcification in patients with chronic kidney disease Stages 3 and 4, with and without diabetes. Nephrol. Dial. Transplant. 2011 Aug;26(8):2582-9
  Stavroulopoulos A et al
  2011/01/01
  
• 備考：
  
• 参照：
  

• No.： 70
• 文献情報：
  Klymiuk N et al. First inducible transgene expression in porcine large animal models. FASEB J. 2012 Mar;26(3):1086-99
  Klymiuk N et al
  2012/01/01
  
• 備考：
  
• 参照：
  

• No.： 71
• 文献情報：
  Josse AR et al. Diets higher in dairy foods and dietary protein support bone health during diet- and exercise-induced weight loss in overweight and obese premenopausal women. J. Clin. Endocrinol. Metab. 2012 Jan;97(1):251-60
  Josse AR et al
  2012/01/01
  
• 備考：
  
• 参照：
  

• No.： 72
• 文献情報：
  Buckle CH et al. Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma. PLoS ONE 2012;7(8):e41127
  Buckle CH et al
  2012/01/01
  
• 備考：
  
• 参照：
  

• No.： 73
• 文献情報：
  Zupan J et al. The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues. J. Biomed. Sci. 2012 Mar;19:28
  Zupan J et al
  2012/01/01
  
• 備考：
  
• 参照：
  

• No.： 74
• 文献情報：
  V叩zquez MA et al. Vertebral fractures in patients with inflammatory bowel disease compared with a healthy population: a prospective case-control study. BMC Gastroenterol 2012 May;12:47
  V叩zquez MA et al
  2012/01/01
  
• 備考：
  
• 参照：
  

• No.： 75
• 文献情報：
  Kaneko K et al. Changes of serum soluble receptor activator for nuclear factor-κB ligand after glucocorticoid therapy reflect regulation of its expression by osteoblasts. J. Clin. Endocrinol. Metab. 2012 Oct;97(10):E1909-17
  Kaneko K et al
  2012/01/01
  
• 備考：
  
• 参照：
  

• No.： 76
• 文献情報：
  Nagashima M et al. Osteogenesis and osteoclast inhibition in rheumatoid arthritis patients treated with bisphosphonates alone or in combination with pitavastatin over an 18-month follow-up after more than 4 years of treatment with bisphosphonates. Arthrit
  Nagashima M et al
  2012/01/01
  
• 備考：
  
• 参照：
  

• No.： 77
• 文献情報：
  Tenta R et al. Bone metabolism compensates for the delayed growth in small for gestational age neonates. Organogenesis ;9(1):55-9
  Tenta R et al
  
• 備考：
  
• 参照：
  

• No.： 78
• 文献情報：
  Schmiedel BJ et al. Receptor activator for NF-κB ligand in acute myeloid leukemia: expression, function, and modulation of NK cell immunosurveillance. J. Immunol. 2013 Jan;190(2):821-31
  Schmiedel BJ et al
  2013/01/01
  
• 備考：
  
• 参照：
  

• No.： 79
• 文献情報：
  Engvall IL et al. Low-dose prednisolone in early rheumatoid arthritis inhibits collagen type I degradation by matrix metalloproteinases as assessed by serum 1CTP--a possible mechanism for specific inhibition of radiological destruction. Rheumatology (Oxfo
  Engvall IL et al
  2013/01/01
  
• 備考：
  
• 参照：
  

• No.： 80
• 文献情報：
  Liu JM et al. An independent positive relationship between the serum total osteocalcin level and fat-free mass in healthy premenopausal women. J. Clin. Endocrinol. Metab. 2013 May;98(5):2146-52
  Liu JM et al
  2013/01/01
  
• 備考：
  
• 参照：
  

• No.： 81
• 文献情報：
  Galeone A et al. Activation of the receptor activator of the nuclear factor-κB ligand pathway during coronary bypass surgery: comparison between on- and off-pump coronary artery bypass surgery procedures. Eur J Cardiothorac Surg 2013 Aug;44(2):e141-
  Galeone A et al
  2013/01/01
  
• 備考：
  
• 参照：
  

• No.： 82
• 文献情報：
  Botella S et al. Traditional and novel bone remodeling markers in premenopausal and postmenopausal women. J. Clin. Endocrinol. Metab. 2013 Nov;98(11):E1740-8
  Botella S et al
  2013/01/01
  
• 備考：
  
• 参照：
  

• No.： 83
• 文献情報：
  Mendon巽a ML et al. Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density. BMC Endocr Disord 2013 Jan;13:1
  Mendon巽a ML et al
  2013/01/01
  
• 備考：
  
• 参照：
  

• No.： 84
• 文献情報：
  Dieckmann M et al. Human apolipoprotein E isoforms differentially affect bone mass and turnover in vivo. J. Bone Miner. Res. 2013 Feb;28(2):236-45
  Dieckmann M et al
  2013/01/01
  
• 備考：
  
• 参照：
  

• No.： 85
• 文献情報：
  Picarda G et al. Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing"s sarcoma by inhibiting RANKL. J Bone Oncol 2013 Sep;2(3):95-104
  Picarda G et al
  2013/01/01
  
• 備考：
  
• 参照：
  

• No.： 86
• 文献情報：
  Saki F et al. Juvenile paget"s disease in an Iranian kindred with vitamin D deficiency and novel homozygous TNFRSF11B mutation. J. Bone Miner. Res. 2013 Jun;28(6):1501-8
  Saki F et al
  2013/01/01
  
• 備考：
  
• 参照：
  

• No.： 87
• 文献情報：
  LaCroix AZ et al. OPG and sRANKL serum levels and incident hip fracture in postmenopausal Caucasian women in the Women"s Health Initiative Observational Study. Bone 2013 Oct;56(2):474-81
  LaCroix AZ et al
  2013/01/01
  
• 備考：
  
• 参照：
  

• No.： 88
• 文献情報：
  Revu S et al. Synovial membrane immunohistology in early-untreated rheumatoid arthritis reveals high expression of catabolic bone markers that is modulated by methotrexate. Arthritis Res. Ther. 2013;15(6):R205
  Revu S et al
  2013/01/01
  
• 備考：
  
• 参照：
  

• No.： 89
• 文献情報：
  Koura HM et al. Relationship between Biochemical Bone Markers and Bone Mineral Density in Patients with Phenylketonuria under Restricted Diet. Iran J Pediatr 2014 Feb;24(1):23-8
  Koura HM et al
  2014/01/01
  
• 備考：
  
• 参照：
  

• No.： 90
• 文献情報：
  Faienza MF et al. Osteoclastogenic potential of peripheral blood mononuclear cells in cleidocranial dysplasia. Int J Med Sci 2014;11(4):356-64
  Faienza MF et al
  2014/01/01
  
• 備考：
  
• 参照：
  

• No.： 91
• 文献情報：
  Metwalley KA et al. Bone mineral status in Egyptian children with classic congenital adrenal hyperplasia. A single-center study from Upper Egypt. Indian J Endocrinol Metab 2014 Sep;18(5):700-4
  Metwalley KA et al
  2014/01/01
  
• 備考：
  
• 参照：
  

• No.： 92
• 文献情報：
  Kawashiri SY et al. Ultrasonographic examination of rheumatoid arthritis patients who are free of physical synovitis: power Doppler subclinical synovitis is associated with bone erosion. Rheumatology (Oxford) 2014 Mar;53(3):562-9
  Kawashiri SY et al
  2014/01/01
  
• 備考：
  
• 参照：
  

• No.： 93
• 文献情報：
  Negredo E et al. Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels. J. Antimicrob. Chemother. 2015 Jul;70(7):2104-7
  Negredo E et al
  2015/01/01
  
• 備考：
  
• 参照：
  

• No.： 94
• 文献情報：
  Vall辿s G et al. Topographical cues regulate the crosstalk between MSCs and macrophages. Biomaterials 2015 Jan;37:124-33
  Vall辿s G et al
  2015/01/01
  
• 備考：
  
• 参照：
  

• No.： 95
• 文献情報：
  Demoulin SA et al. Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic dendritic cells via RANKL secretion. Oncoimmunology 2015 Jun;4(6):e1008334
  Demoulin SA et al
  2015/01/01
  
• 備考：
  
• 参照：
  

• No.： 96
• 文献情報：
  Kastritis E et al. Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging. Blood Cancer J 2015 Jun;5:e319
  Kastritis E et al
  2015/01/01
  
• 備考：
  
• 参照：
  

• No.： 97
• 文献情報：
  Pitari MR et al. Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts. Oncotarget 2015 Sep;6(29):27343-58
  Pitari MR et al
  2015/01/01
  
• 備考：
  
• 参照：
  

• No.： 98
• 文献情報：
  Kurz K et al. Effects of Antitumor Necrosis Factor Therapy on Osteoprotegerin, Neopterin, and sRANKL Concentrations in Patients with Rheumatoid Arthritis. Dis. Markers 2015;2015:276969
  Kurz K et al
  2015/01/01
  
• 備考：
  
• 参照：
  

• No.： 99
• 文献情報：
  Melchiorre D et al. Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A. Haematologica 2016 Feb;101(2):219-25
  Melchiorre D et al
  2016/01/01
  
• 備考：
  
• 参照：
  

• No.： 100
• 文献情報：
  Kikuta J et al. Notch signaling induces root resorption via RANKL and IL-6 from hPDL cells. J. Dent. Res. 2015 Jan;94(1):140-7
  Kikuta J et al
  2015/01/01
  
• 備考：
  
• 参照：
  

• No.： 101
• 文献情報：
  Anastasilakis AD et al. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid. Osteoporos Int 2015 Oct;26(10):2521-7
  Anastasilakis AD et al
  2015/01/01
  
• 備考：
  
• 参照：
  

• No.： 102
• 文献情報：
  Oster M et al. Toward improved phosphorus efficiency in monogastrics-interplay of serum, minerals, bone, and immune system after divergent dietary phosphorus supply in swine. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2016 05;310(10):R917-25
  Oster M et al
  2016/01/01
  
• 備考：
  
• 参照：
  

• No.： 103
• 文献情報：
  Schock H et al. Hormone concentrations throughout uncomplicated pregnancies: a longitudinal study. BMC Pregnancy Childbirth 2016 Jul;16(1):146
  Schock H et al
  2016/01/01
  
• 備考：
  
• 参照：
  

• No.： 104
• 文献情報：
  Remuzgo-Mart鱈nez S et al. Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis. Sci Rep 2016 Jul;6:29713
  Remuzgo-Mart鱈nez S et al
  2016/01/01
  
• 備考：
  
• 参照：
  

• No.： 105
• 文献情報：
  Gifre L et al. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy. Osteoporos Int 2017 09;28(9):2707-2715
  Gifre L et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 106
• 文献情報：
  Ugay L et al. Role of Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand in Bone Loss Related to Advanced Chronic Obstructive Pulmonary Disease. Chin. Med. J. 2016 Jul;129(14):1696-703
  Ugay L et al
  2016/01/01
  
• 備考：
  
• 参照：
  

• No.： 107
• 文献情報：
  Adami G et al. Hajdu Cheney Syndrome; report of a novel NOTCH2 mutation and treatment with denosumab. Bone 2016 11;92:150-156
  Adami G et al
  2016/01/01
  
• 備考：
  
• 参照：
  

• No.： 108
• 文献情報：
  Irtyuga O et al. NOTCH1 Mutations in Aortic Stenosis: Association with Osteoprotegerin/RANK/RANKL. Biomed Res Int 2017;2017:6917907
  Irtyuga O et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 109
• 文献情報：
  Bruhn-Olszewska B et al. Prevalence of polymorphisms in OPG, RANKL and RANK as potential markers for Charcot arthropathy development. Sci Rep 2017 03;7(1):501
  Bruhn-Olszewska B et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 110
• 文献情報：
  Hauser B et al. Autoantibodies to Osteoprotegerin are Associated with Low Hip Bone Mineral Density and History of Fractures in Axial Spondyloarthritis: A Cross-Sectional Observational Study. Calcif. Tissue Int. 2017 10;101(4):375-383
  Hauser B et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 111
• 文献情報：
  Sarink D et al. Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort. Cancer Prev Res (Phila) 2017 Sep;10(9):525-534
  Sarink D et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 112
• 文献情報：
  Perp辿tuo IP et al. Methotrexate and low-dose prednisolone downregulate osteoclast function by decreasing receptor activator of nuclear factor-κβ expression in monocytes from patients with early rheumatoid arthritis. RMD Open 2017;3(1):e000365
  Perp辿tuo IP et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 113
• 文献情報：
  ナ嗟iwicka E et al. Serum irisin and myostatin levels after 2 weeks of high-altitude climbing. PLoS ONE 2017;12(7):e0181259
  ナ嗟iwicka E et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 114
• 文献情報：
  Lambert MNT et al. Combined bioavailable isoflavones and probiotics improve bone status and estrogen metabolism in postmenopausal osteopenic women: a randomized controlled trial. Am. J. Clin. Nutr. 2017 Sep;106(3):909-920
  Lambert MNT et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 115
• 文献情報：
  Kiechl S et al. Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer. Oncotarget 2017 Jan;8(3):3811-3825
  Kiechl S et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 116
• 文献情報：
  Salda単a L et al. Paracrine interactions between mesenchymal stem cells and macrophages are regulated by 1,25-dihydroxyvitamin D3. Sci Rep 2017 11;7(1):14618
  Salda単a L et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 117
• 文献情報：
  Mart鱈n-Saavedra F et al. Substrate Microarchitecture Shapes the Paracrine Crosstalk of Stem Cells with Endothelial Cells and Osteoblasts. Sci Rep 2017 11;7(1):15182
  Mart鱈n-Saavedra F et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 118
• 文献情報：
  Chrysis D et al. Osteoprotegerin, RANKL, ADMA, and Fetuin-A serum levels in children with type I diabetes mellitus. Pediatr Diabetes 2017 06;18(4):277-282
  Chrysis D et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 119
• 文献情報：
  Castroflorio T et al. Biochemical markers of bone metabolism during early orthodontic tooth movement with aligners. Angle Orthod 2017 Jan;87(1):74-81
  Castroflorio T et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 120
• 文献情報：
  Wu B et al. Craniometaphyseal dysplasia with obvious biochemical abnormality and rickets-like features. Clin. Chim. Acta 2016 May;456:122-127
  Wu B et al
  2016/01/01
  
• 備考：
  
• 参照：
  

• No.： 121
• 文献情報：
  Lange U et al. Weekly oral bisphosphonates over 2 years prevent bone loss in cardiac transplant patients. Clin Transplant 2017 Nov;31(11)
  Lange U et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 122
• 文献情報：
  Bersezio C et al. Does the Use of a "Walking Bleaching" Technique Increase Bone Resorption Markers? Oper Dent ;43(3):250-260
  Bersezio C et al
  
• 備考：
  
• 参照：
  

• No.： 123
• 文献情報：
  Eleutherakis-Papaiakovou E et al. Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk 2018 06;18(6):431-437
  Eleutherakis-Papaiakovou E et al
  2018/01/01
  
• 備考：
  
• 参照：
  

• No.： 124
• 文献情報：
  Serrano-Pi単a R et al. sRANKL and its correlation with metabolic syndrome parameters in children. Int J Paediatr Dent 2018 Nov;28(6):633-640
  Serrano-Pi単a R et al
  2018/01/01
  
• 備考：
  
• 参照：
  

• No.： 125
• 文献情報：
  Glasnović A et al. RANKL/RANK/OPG Axis Is Deregulated in the Cerebrospinal Fluid of Multiple Sclerosis Patients at Clinical Onset. Neuroimmunomodulation 2018;25(1):23-33
  Glasnović A et al
  2018/01/01
  
• 備考：
  
• 参照：
  

• No.： 126
• 文献情報：
  Davenport C et al. RANKL Inhibits the Production of Osteoprotegerin from Smooth Muscle Cells under Basal Conditions and following Exposure to Cyclic Strain. J. Vasc. Res. 2018;55(2):111-123
  Davenport C et al
  2018/01/01
  
• 備考：
  
• 参照：
  

• No.： 127
• 文献情報：
  Kardos Z et al. Increased frequency of temporal acoustic window failure in rheumatoid arthritis: a manifestation of altered bone metabolism? Clin. Rheumatol. 2018 May;37(5):1183-1188
  Kardos Z et al
  2018/01/01
  
• 備考：
  
• 参照：
  

• No.： 128
• 文献情報：
  Moschen AR et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005 Apr;54(4):479-87
  Moschen AR et al
  2005/01/01
  
• 備考：
  
• 参照：
  

• No.： 129
• 文献情報：
  Abrahamsen B et al. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. Bone 2005 Apr;36(4):727-35
  Abrahamsen B et al
  2005/01/01
  
• 備考：
  
• 参照：
  

• No.： 130
• 文献情報：
  Bezerra MC et al. Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis. Rheumatology (Oxford) 2005 Dec;44(12):1503-6
  Bezerra MC et al
  2005/01/01
  
• 備考：
  
• 参照：
  

• No.： 131
• 文献情報：
  Chan MH et al. Specific biochemical markers of bone metabolism and cytokine study confirm the diagnosis of malignant infantile osteopetrosis at birth using cord blood sample. Pathology 2005 Feb;37(1):51-5
  Chan MH et al
  2005/01/01
  
• 備考：
  
• 参照：
  

• No.： 132
• 文献情報：
  Zojer N et al. Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients. Anticancer Res. ;25(5):3607-12
  Zojer N et al
  
• 備考：
  
• 参照：
  

• No.： 133
• 文献情報：
  Ishii R et al. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis. Pediatr Blood Cancer 2006 Aug;47(2):194-9
  Ishii R et al
  2006/01/01
  
• 備考：
  
• 参照：
  

• No.： 134
• 文献情報：
  Sylvester FA et al. Are activated T cells regulators of bone metabolism in children with Crohn disease? J. Pediatr. 2006 Apr;148(4):461-6
  Sylvester FA et al
  2006/01/01
  
• 備考：
  
• 参照：
  

• No.： 135
• 文献情報：
  Albalate M et al. Association between phosphate removal and markers of bone turnover in haemodialysis patients. Nephrol. Dial. Transplant. 2006 Jun;21(6):1626-32
  Albalate M et al
  2006/01/01
  
• 備考：
  
• 参照：
  

• No.： 136
• 文献情報：
  Martini G et al. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Pagets disease of bone. Bone 2007 Feb;40(2):457-63
  Martini G et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 137
• 文献情報：
  Ozer FF et al. Relation of RANKL and OPG Levels with Bone Resorption in Patients with Acromegaly and Prolactinoma. Horm. Metab. Res. 2018 Jul;50(7):562-567
  Ozer FF et al
  2018/01/01
  
• 備考：
  
• 参照：
  

• No.： 138
• 文献情報：
  Voorzanger-Rousselot N et al. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation. Br. J. Cancer 2006 Aug;95(4):506-14
  Voorzanger-Rousselot N et al
  2006/01/01
  
• 備考：
  
• 参照：
  

• No.： 139
• 文献情報：
  Secchiero P et al. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am. J. Pathol. 2006 Dec;169(6):2236-44
  Secchiero P et al
  2006/01/01
  
• 備考：
  
• 参照：
  

• No.： 140
• 文献情報：
  Roato I et al. IL-7 up-regulates TNF-alpha-dependent osteoclastogenesis in patients affected by solid tumor. PLoS ONE 2006 Dec;1:e124
  Roato I et al
  2006/01/01
  
• 備考：
  
• 参照：
  

• No.： 141
• 文献情報：
  Terpos E et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br. J. Haematol. 2006 Dec;135(5):688-92
  Terpos E et al
  2006/01/01
  
• 備考：
  
• 参照：
  

• No.： 142
• 文献情報：
  Terpos E et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoproteger
  Terpos E et al
  2005/01/01
  
• 備考：
  
• 参照：
  

• No.： 143
• 文献情報：
  Rouster-Stevens KA et al. RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis. Arthritis Rheum. 2007 Mar;56(3):977-83
  Rouster-Stevens KA et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 144
• 文献情報：
  Lequerr辿 T et al. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab. Rheumatology (Oxford) 2007 Mar;46(3):446-53
  Lequerr辿 T et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 145
• 文献情報：
  Morabito N et al. The "lively" cytokines network in beta-Thalassemia Major-related osteoporosis. Bone 2007 Jun;40(6):1588-94
  Morabito N et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 146
• 文献情報：
  Monegal A et al. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease. Liver Int. 2007 May;27(4):492-7
  Monegal A et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 147
• 文献情報：
  Mora S et al. Alterations in circulating osteoimmune factors may be responsible for high bone resorption rate in HIV-infected children and adolescents. AIDS 2007 May;21(9):1129-35
  Mora S et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 148
• 文献情報：
  Mangiafico RA et al. Increased formation of 8-iso-prostaglandin F(2alpha) is associated with altered bone metabolism and lower bone mass in hypercholesterolaemic subjects. J. Intern. Med. 2007 Jun;261(6):587-96
  Mangiafico RA et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 149
• 文献情報：
  Whyte MP et al. Juvenile Pagets disease: the second reported, oldest patient is homozygous for the TNFRSF11B "Balkan" mutation (966_969delTGACinsCTT), which elevates circulating immunoreactive osteoprotegerin levels. J. Bone Miner. Res. 2007 Jun;22(6):938
  Whyte MP et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 150
• 文献情報：
  Goranova-Marinova V et al. Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations. Haematologica 2007 Jul;92(7):1000-1
  Goranova-Marinova V et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 151
• 文献情報：
  Kiechl S et al. Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. Circulation 2007 Jul;116(4):385-91
  Kiechl S et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 152
• 文献情報：
  Miheller P et al. Changes of OPG and RANKL concentrations in Crohns disease after infliximab therapy. Inflamm. Bowel Dis. 2007 Nov;13(11):1379-84
  Miheller P et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 153
• 文献情報：
  Mogi M et al. Expression of cathepsin-K in gingival crevicular fluid of patients with periodontitis. Arch. Oral Biol. 2007 Sep;52(9):894-8
  Mogi M et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 154
• 文献情報：
  Suh KT et al. Elevated soluble receptor activator of nuclear factor-kappaB ligand and reduced bone mineral density in patients with adolescent idiopathic scoliosis. Eur Spine J 2007 Oct;16(10):1563-9
  Suh KT et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 155
• 文献情報：
  Pietschmann P et al. Bone structure and metabolism in a rodent model of male senile osteoporosis. Exp. Gerontol. 2007 Nov;42(11):1099-108
  Pietschmann P et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 156
• 文献情報：
  Andersson MK et al. Effects on osteoclast and osteoblast activities in cultured mouse calvarial bones by synovial fluids from patients with a loose joint prosthesis and from osteoarthritis patients. Arthritis Res. Ther. 2007;9(1):R18
  Andersson MK et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 157
• 文献情報：
  Kubota T et al. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor. Arthritis Res. The
  Kubota T et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 158
• 文献情報：
  Nakchbandi IA et al. The role of the receptor activator of nuclear factor-kappaB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 2008 Mar;93(3):967-73
  Nakchbandi IA et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 159
• 文献情報：
  Zhao HY et al. Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women. Osteoporos Int 2008 Feb;19(2):221-6
  Zhao HY et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 160
• 文献情報：
  Santiago RA et al. Bone mineral apparent density in juvenile dermatomyositis: the role of lean body mass and glucocorticoid use. Scand. J. Rheumatol. ;37(1):40-7
  Santiago RA et al
  
• 備考：
  
• 参照：
  

• No.： 161
• 文献情報：
  Mangiafico RA et al. Increased augmentation index and central aortic blood pressure in osteoporotic postmenopausal women. Osteoporos Int 2008 Jan;19(1):49-56
  Mangiafico RA et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 162
• 文献情報：
  Galusca B et al. Constitutional thinness: unusual human phenotype of low bone quality. J. Clin. Endocrinol. Metab. 2008 Jan;93(1):110-7
  Galusca B et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 163
• 文献情報：
  Nakajima R et al. Effects of compression force on fibroblast growth factor-2 and receptor activator of nuclear factor kappa B ligand production by periodontal ligament cells in vitro. J. Periodont. Res. 2008 Apr;43(2):168-73
  Nakajima R et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 164
• 文献情報：
  Anastasilakis AD et al. Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappaB ligand levels in women with established osteoporosis treated with teriparatide. Eur. J. Endocrinol. 2008 Mar;158(3):411-5
  Anastasilakis AD et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 165
• 文献情報：
  D"Amelio P et al. Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. J. Bone Miner. Res. 2008 Mar;23(3):373-9
  D"Amelio P et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 166
• 文献情報：
  Morishita M et al. Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. J. Rheumatol. 2008 Mar;35(3):407-13
  Morishita M et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 167
• 文献情報：
  Pilichou A et al. High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-kappa B ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis. Clin. Bioch
  Pilichou A et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 168
• 文献情報：
  Kwan Tat S et al. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells. Clin.
  Kwan Tat S et al
  
• 備考：
  
• 参照：
  

• No.： 169
• 文献情報：
  Bakhireva LN et al. Does osteoprotegerin or receptor activator of nuclear factor-kappaB ligand mediate the association between bone and coronary artery calcification? J. Clin. Endocrinol. Metab. 2008 May;93(5):2009-12
  Bakhireva LN et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 170
• 文献情報：
  Gendron S et al. Alpha1beta1 integrin and interleukin-7 receptor up-regulate the expression of RANKL in human T cells and enhance their osteoclastogenic function. Immunology 2008 Nov;125(3):359-69
  Gendron S et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 171
• 文献情報：
  Kerschan-Schindl K et al. Serum levels of receptor activator of nuclear factor kappaB ligand (RANKL) in healthy women and men. Exp. Clin. Endocrinol. Diabetes 2008 Aug;116(8):491-5
  Kerschan-Schindl K et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 172
• 文献情報：
  Escobar-Morreale HF et al. Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome. Eur. J. Endocrinol. 2008 Sep;159(3):225-32
  Escobar-Morreale HF et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 173
• 文献情報：
  Giner M et al. Modifying RANKL/OPG mRNA expression in differentiating and growing human primary osteoblasts. Horm. Metab. Res. 2008 Dec;40(12):869-74
  Giner M et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 174
• 文献情報：
  Fahrleitner-Pammer A et al. Bone markers predict cardiovascular events in chronic kidney disease. J. Bone Miner. Res. 2008 Nov;23(11):1850-8
  Fahrleitner-Pammer A et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 175
• 文献情報：
  Spelling P et al. Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker? Scand. J. Rheumatol. ;37(6):439-44
  Spelling P et al
  
• 備考：
  
• 参照：
  

• No.： 176
• 文献情報：
  Rauner M et al. The HLA-B27 transgenic rat, a model of spondyloarthritis, has decreased bone mineral density and increased RANKL to osteoprotegerin mRNA ratio. J. Rheumatol. 2009 Jan;36(1):120-6
  Rauner M et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 177
• 文献情報：
  Nenseter MS et al. Dysregulated RANK ligand/RANK axis in hyperhomocysteinemic subjects: effect of treatment with B-vitamins. Stroke 2009 Jan;40(1):241-7
  Nenseter MS et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 178
• 文献情報：
  Gua単abens N et al. High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue. J. Bone Miner. Metab. 2009;27(3):347-54
  Gua単abens N et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 179
• 文献情報：
  Turk N et al. Proinflammatory cytokines and receptor activator of nuclear factor kappaB-ligand/osteoprotegerin associated with bone deterioration in patients with Crohns disease. Eur J Gastroenterol Hepatol 2009 Feb;21(2):159-66
  Turk N et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 180
• 文献情報：
  Honsawek S et al. Relationships between OPG, RANKL, bone metabolism, and bone mineral density in biliary atresia. Pediatr. Surg. Int. 2009 Mar;25(3):261-7
  Honsawek S et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 181
• 文献情報：
  Karapanagiotou EM et al. Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients. Med. Oncol. 2010 Jun;27(2):332-8
  Karapanagiotou EM et al
  2010/01/01
  
• 備考：
  
• 参照：
  

• No.： 182
• 文献情報：
  Terpos E et al. The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. Anticancer Res. 2009 May;29(5):1651-7
  Terpos E et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 183
• 文献情報：
  Faienza MF et al. Osteoclastogenesis in children with 21-hydroxylase deficiency on long-term glucocorticoid therapy: the role of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin imbalance. J. Clin. Endocrinol. Metab. 2009 Jul;94(7):2269-
  Faienza MF et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 184
• 文献情報：
  J淡rgensen L et al. Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study. Osteoporos Int 2010 Jun;21(6):931-8
  J淡rgensen L et al
  2010/01/01
  
• 備考：
  
• 参照：
  

• No.： 185
• 文献情報：
  Rauchenzauner M et al. Chronic antiepileptic monotherapy, bone metabolism, and body composition in non-institutionalized children. Dev Med Child Neurol 2010 Mar;52(3):283-8
  Rauchenzauner M et al
  2010/01/01
  
• 備考：
  
• 参照：
  

• No.： 186
• 文献情報：
  Kerschan-Schindl K et al. A 246-km continuous running race causes significant changes in bone metabolism. Bone 2009 Dec;45(6):1079-83
  Kerschan-Schindl K et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 187
• 文献情報：
  Rendina D et al. Bone turnover and the osteoprotegerin-RANKL pathway in tumor-induced osteomalacia: a longitudinal study of five cases. Calcif. Tissue Int. 2009 Oct;85(4):293-300
  Rendina D et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 188
• 文献情報：
  Mizutani K et al. Prostate cancer promotes CD11b positive cells to differentiate into osteoclasts. J. Cell. Biochem. 2009 Mar;106(4):563-9
  Mizutani K et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 189
• 文献情報：
  Marchelli D et al. Increased serum OPG in atrophic nonunion shaft fractures. J Orthop Traumatol 2009 Jun;10(2):55-8
  Marchelli D et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 190
• 文献情報：
  Syversen U et al. Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. BMC Endocr Disord 2009 Mar;9:10
  Syversen U et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 191
• 文献情報：
  Kim JG et al. Non-association between polymorphisms of the frizzled receptor genes and bone mineral density in postmenopausal Korean women. J. Korean Med. Sci. 2009 Jun;24(3):443-7
  Kim JG et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 192
• 文献情報：
  Sauer AV et al. ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency. Blood 2009 Oct;114(15):3216-26
  Sauer AV et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 193
• 文献情報：
  Gonz叩lez-Calvin JL et al. Bone mineral density and serum levels of soluble tumor necrosis factors, estradiol, and osteoprotegerin in postmenopausal women with cirrhosis after viral hepatitis. J. Clin. Endocrinol. Metab. 2009 Dec;94(12):4844-50
  Gonz叩lez-Calvin JL et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 194
• 文献情報：
  D"Amelio P et al. Alendronate reduces osteoclast precursors in osteoporosis. Osteoporos Int 2010 Oct;21(10):1741-50
  D"Amelio P et al
  2010/01/01
  
• 備考：
  
• 参照：
  

• No.： 195
• 文献情報：
  Camozzi V et al. Persistent increase of osteoprotegerin levels after cortisol normalization in patients with Cushings syndrome. Eur. J. Endocrinol. 2010 Jan;162(1):85-90
  Camozzi V et al
  2010/01/01
  
• 備考：
  
• 参照：
  

• No.： 196
• 文献情報：
  Roato I et al. Bone impairment in phenylketonuria is characterized by circulating osteoclast precursors and activated T cell increase. PLoS ONE 2010 Nov;5(11):e14167
  Roato I et al
  2010/01/01
  
• 備考：
  
• 参照：
  

• No.： 197
• 文献情報：
  Dalbeth N et al. Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. Arthritis Res. Ther. 2010;12(4):R164
  Dalbeth N et al
  2010/01/01
  
• 備考：
  
• 参照：
  

• No.： 198
• 文献情報：
  Paternoster L et al. Genome-wide association meta-analysis of cortical bone mineral density unravels allelic heterogeneity at the RANKL locus and potential pleiotropic effects on bone. PLoS Genet. 2010 Nov;6(11):e1001217
  Paternoster L et al
  2010/01/01
  
• 備考：
  
• 参照：
  

• No.： 199
• 文献情報：
  Jorde R et al. No significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year. Nutr J 2010 Jan;9:1
  Jorde R et al
  2010/01/01
  
• 備考：
  
• 参照：
  

• No.： 200
• 文献情報：
  Abd El Dayem SM et al. Bone mineral density, bone turnover markers, lean mass, and fat mass in Egyptian children with congenital adrenal hyperplasia. Arch Med Sci 2010 Mar;6(1):104-10
  Abd El Dayem SM et al
  2010/01/01
  
• 備考：
  
• 参照：
  

• No.： 201
• 文献情報：
  Id Boufker H et al. The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. BMC Cancer 2010 Jun;10:298
  Id Boufker H et al
  2010/01/01
  
• 備考：
  
• 参照：
  

• No.： 202
• 文献情報：
  Wasilewska A et al. Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children. Pediatr. Nephrol. 2010 Oct;25(10):2067-75
  Wasilewska A et al
  2010/01/01
  
• 備考：
  
• 参照：
  

• No.： 203
• 文献情報：
  Colombini A et al. Plasma and drainage fluid levels of soluble receptor activator of nuclear factor-kB (sRANK), soluble receptor activator of nuclear factor-kB ligand (sRANKL) and osteoprotegerin (OPG) during proximal humerus fracture healing. Int Orthop
  Colombini A et al
  2011/01/01
  
• 備考：
  
• 参照：
  

• No.： 204
• 文献情報：
  Rauner M et al. Dissociation of osteogenic and immunological effects by the selective glucocorticoid receptor agonist, compound A, in human bone marrow stromal cells. Endocrinology 2011 Jan;152(1):103-12
  Rauner M et al
  2011/01/01
  
• 備考：
  
• 参照：
  

• No.： 205
• 文献情報：
  Pepene CE et al. Circulating osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction. Eur. J. Endocrinol. 2011 Jan;164(1):61-8
  Pepene CE et al
  2011/01/01
  
• 備考：
  
• 参照：
  

• No.： 206
• 文献情報：
  J淡rgensen L et al. Serum osteoprotegerin levels are related to height loss: the Tromsø Study. Eur. J. Epidemiol. 2011 Apr;26(4):305-12
  J淡rgensen L et al
  2011/01/01
  
• 備考：
  
• 参照：
  

• No.： 207
• 文献情報：
  Terpos E et al. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. Clin. Exp. Rheumatol. ;29(6):921-5
  Terpos E et al
  
• 備考：
  
• 参照：
  

• No.： 208
• 文献情報：
  Bergstr旦m I et al. Physical training increases osteoprotegerin in postmenopausal women. J. Bone Miner. Metab. 2012 Mar;30(2):202-7
  Bergstr旦m I et al
  2012/01/01
  
• 備考：
  
• 参照：
  

• No.： 209
• 文献情報：
  Wu B et al. Atypical skeletal manifestations of rickets in a familial hypocalciuric hypercalcemia patient. Bone Res 2017;5:17001
  Wu B et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 210
• 文献情報：
  Rachner TD et al. Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer. Clin. Cancer Res. 2019 Feb;25(4):1369-1378
  Rachner TD et al
  2019/01/01
  
• 備考：
  
• 参照：
  

• No.： 211
• 文献情報：
  Evenepoel P et al. Poor Vitamin K Status Is Associated With Low Bone Mineral Density and Increased Fracture Risk in End-Stage Renal Disease. J. Bone Miner. Res. 2019 Feb;34(2):262-269
  Evenepoel P et al
  2019/01/01
  
• 備考：
  
• 参照：
  

• No.： 212
• 文献情報：
  Sarink D et al. Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort. BMC Cancer 2018 Oct;18(1):1010
  Sarink D et al
  2018/01/01
  
• 備考：
  
• 参照：
  

• No.： 213
• 文献情報：
  Mantovani A et al. Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes. Diabetes Metab. 2019 09;45(4):347-355
  Mantovani A et al
  2019/01/01
  
• 備考：
  
• 参照：
  

• No.： 214
• 文献情報：
  Terpos E et al. Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates. Am. J. Hematol. 20
  Terpos E et al
  2019/01/01
  
• 備考：
  
• 参照：
  

• No.： 215
• 文献情報：
  Evenepoel P et al. A distinct bone phenotype in ADPKD patients with end-stage renal disease. Kidney Int. 2019 02;95(2):412-419
  Evenepoel P et al
  2019/01/01
  
• 備考：
  
• 参照：
  

• No.： 216
• 文献情報：
  Frost M et al. Absence of an osteopetrosis phenotype in IKBKG (NEMO) mutation-positive women: A case-control study. Bone 2019 Apr;121:243-254
  Frost M et al
  2019/01/01
  
• 備考：
  
• 参照：
  

• No.： 217
• 文献情報：
  Terpos E et al. Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. Int. J. Cancer 2019 Jul;145(2):559-568
  Terpos E et al
  2019/01/01
  
• 備考：
  
• 参照：
  

• No.： 218
• 文献情報：
  Fassio A et al. Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women. Bone 2019 Jun;123:191-195
  Fassio A et al
  2019/01/01
  
• 備考：
  
• 参照：
  

• No.： 219
• 文献情報：
  Evenepoel P et al. Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients. Kidney Int. 2019 Jun;95(6):1461-1470
  Evenepoel P et al
  2019/01/01
  
• 備考：
  
• 参照：